Island Pharmaceuticals Income Statement

Financials in millions AUD. Fiscal year is July - June.

Millions AUD. Fiscal year is Jul - Jun.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022
Operating Revenue	0.28	0.11	1.25	-	-
Other Revenue	-	0.01	0.01	-	-
Revenue	0.28	0.12	1.26	-	-
Revenue Growth	137.71%	-90.57%	-	-	-
Cost of Revenue	2.86	1.4	2.27	1.14	-
Gross Profit	-2.58	-1.29	-1.01	-1.14	-
Selling, General & Admin	2.6	2.33	1.85	1.77	1.78
Research & Development	-	-	-	-	1.03
Operating Expenses	7.75	2.67	1.85	1.77	2.81
Operating Income	-10.33	-3.96	-2.86	-2.91	-2.81
Interest Expense	-	-0.03	-0.05	-0.01	-
Interest & Investment Income	0.28	0.06	0	0.01	-
Currency Exchange Gain (Loss)	0.21	0	0.04	0.08	0.2
Pretax Income	-9.84	-3.92	-2.86	-2.83	-2.61
Net Income	-9.84	-3.92	-2.86	-2.83	-2.61
Net Income to Common	-9.84	-3.92	-2.86	-2.83	-2.61
Net Income Growth	-	-	-	-	-
Shares Outstanding (Basic)	270	173	90	81	81
Shares Outstanding (Diluted)	270	173	90	81	81
Shares Change	55.94%	91.98%	11.11%	0.42%	334.32%
EPS (Basic)	-0.04	-0.02	-0.03	-0.03	-0.03
EPS (Diluted)	-0.04	-0.02	-0.03	-0.03	-0.03
EPS Growth	-	-	-	-	-

Additional Metrics

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022
Gross Margin	-	-	-80.14%	-	-
Operating Margin	-3656.30%	-3326.06%	-227.00%	-	-
Profit Margin	-3482.66%	-3296.73%	-227.04%	-	-
EBITDA	-10.23	-	-	-	-
D&A For EBITDA	0.11	-	-	-	-
EBIT	-10.33	-3.96	-2.86	-2.91	-2.81
EBIT Margin	-	-	-227.00%	-	-
Revenue as Reported	0.56	0.18	1.27	0.01	-